Forecasting the Fallout from AMR: Averting the Health and Economic Impacts Through One Health Policy and Investment
This brief presents policy recommendations on how to mitigate the potential economic impacts of antimicrobial resistance (AMR).
Fifi Olumogba is a research analyst working in health and wellbeing at RAND Europe. She has a broad range of research interests, including disparities within health care, healthcare innovations and health services improvement. Olumogba has supported various research projects within the team and has experience in both qualitative and quantitative research methods. She has previously worked on a healthcare improvement review looking at mapping the various methodologies used in quality improvement initiatives within healthcare, a national quality improvement programme to reduce avoidable brain injury in Childbirth in England, and a rapid evaluation looking at understanding the extent of vertical integration of primary care services into acute hospital trusts in England. Olumogba has experience working with a range of clients across government and healthcare industry such as Genomics England, Idorsia, Pfizer, Department of Health and social care and the Food Security Agency. She has interests in healthcare innovation, policy, and health systems and services improvement.
Before joining RAND, Olumogba completed her Master of Public Health at Imperial College London. Her thesis explored the role of information access, processing of information, personal experiences and its impact on attitudes and behaviours towards the COVID-19 vaccination. She holds a B.Sc (Hons) in biomdeical science form the University of Essex.
Education
M.P.H. in public health, Imperial College London; B.Sc. in biomedical science, University of Essex
Languages
English